Open Access<p>Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells</p>
Author(s) -
Bessi Qorri,
William Harless,
Myron R. Szewczuk
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s264122
Subject(s) - cancer research , epidermal growth factor receptor , apoptosis , pancreatic cancer , mechanism (biology) , signal transduction , epidermal growth factor , growth factor receptor , chemistry , receptor , medicine , pharmacology , cancer , microbiology and biotechnology , biology , biochemistry , philosophy , epistemology
Aspirin (acetylsalicylic acid) and celecoxib have been used as potential anti-cancer therapies. Aspirin exerts its therapeutic effect in both cyclooxygenase (COX)-dependent and -independent pathways to reduce tumor growth and disable tumorigenesis. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces factors that cause inflammation and pain. The question is whether aspirin and celecoxib have other molecular targets of equal or more therapeutic efficacy with significant anti-cancer preventive benefits.